Hege S Haugnes

Summary

Publications

  1. doi request reprint Assessment of late urinary, bowel and sexual function after dose escalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer
    Hege S Haugnes
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Scand J Urol Nephrol 46:124-32. 2012
  2. doi request reprint Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up
    Hege S Haugnes
    Oncology Department, University Hospital of North Norway, Tromsø, Norway
    J Clin Oncol 30:3752-63. 2012
  3. doi request reprint High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)
    Hege S Haugnes
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Acta Oncol 51:168-76. 2012
  4. doi request reprint Pulmonary function in long-term survivors of testicular cancer
    Hege S Haugnes
    Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Tromsø N 9037, Norway
    J Clin Oncol 27:2779-86. 2009
  5. doi request reprint Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study
    Hege S Haugnes
    Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
    J Clin Oncol 28:4649-57. 2010
  6. ncbi request reprint Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors
    Mette Sprauten
    Mette Sprauten, Milada Cvancarova, Sophie D Fosså, and Jan Oldenburg, Oslo University Hospital Trine Bjøro, Oslo University Hospital and University of Oslo Johan Bjerner, Fürst Medical Laboratory, Oslo Marianne Brydøy, University of Bergen, Bergen and Hege S Haugnes, University of Tromsø and University Hospital of North Norway, Tromsø, Norway
    J Clin Oncol 32:571-8. 2014

Collaborators

Detail Information

Publications6

  1. doi request reprint Assessment of late urinary, bowel and sexual function after dose escalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer
    Hege S Haugnes
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Scand J Urol Nephrol 46:124-32. 2012
    ....
  2. doi request reprint Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up
    Hege S Haugnes
    Oncology Department, University Hospital of North Norway, Tromsø, Norway
    J Clin Oncol 30:3752-63. 2012
    ..Moreover, we postulate recommendations for general medical evaluations that should begin after treatment is completed and continue during follow-up...
  3. doi request reprint High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)
    Hege S Haugnes
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Acta Oncol 51:168-76. 2012
    ..The aim of this study was to present survival and toxicity data for patients treated with high-dose chemotherapy (HDCT) within the SWENOTECA IV cancer care program...
  4. doi request reprint Pulmonary function in long-term survivors of testicular cancer
    Hege S Haugnes
    Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Tromsø N 9037, Norway
    J Clin Oncol 27:2779-86. 2009
    ..Long-term toxicity after cancer treatment has gained increasing clinical attention. We evaluated pulmonary function in long-term survivors of testicular cancer (TC)...
  5. doi request reprint Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study
    Hege S Haugnes
    Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
    J Clin Oncol 28:4649-57. 2010
    ..To evaluate the prevalence of cardiovascular risk factors and long-term incidence of cardiovascular disease (CVD) in survivors of testicular cancer (TC)...
  6. ncbi request reprint Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors
    Mette Sprauten
    Mette Sprauten, Milada Cvancarova, Sophie D Fosså, and Jan Oldenburg, Oslo University Hospital Trine Bjøro, Oslo University Hospital and University of Oslo Johan Bjerner, Fürst Medical Laboratory, Oslo Marianne Brydøy, University of Bergen, Bergen and Hege S Haugnes, University of Tromsø and University Hospital of North Norway, Tromsø, Norway
    J Clin Oncol 32:571-8. 2014
    ..To assess longitudinal long-term alterations of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in testicular cancer survivors (TCSs)...